GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Wolwo Bio-Pharmaceutical Co 300357.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

22.09

-2.00%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.06bn

FY2016FY2025

Net income

CN¥380.9m

FY2016FY2025

Free cash flow

CN¥303.8m

FY2016FY2025

Shareholders' equity

CN¥2.62bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.06bnCN¥925.4mCN¥848.2mCN¥896.0mCN¥807.7mCN¥636.2mCN¥639.4mCN¥500.7mCN¥385.6mCN¥312.1m
Gross profitCN¥1.01bnCN¥880.6mCN¥808.0mCN¥853.5mCN¥773.3mCN¥607.7mCN¥616.5mCN¥472.2mCN¥371.5mCN¥300.5m
Research and developmentCN¥117.1mCN¥119.9mCN¥112.2mCN¥106.0mCN¥87.9mCN¥64.9mCN¥41.2mCN¥13.5mCN¥7.7mCN¥9.2m
Operating incomeCN¥414.4mCN¥369.1mCN¥345.0mCN¥396.2mCN¥392.9mCN¥321.5mCN¥343.4mCN¥271.4mCN¥216.2mCN¥151.5m
Net incomeCN¥380.9mCN¥317.8mCN¥310.2mCN¥348.8mCN¥338.0mCN¥278.4mCN¥298.3mCN¥232.9mCN¥186.1mCN¥129.2m
Diluted earnings per share0.730.610.590.670.650.530.570.440.360.25

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥2.90bnCN¥2.71bnCN¥2.56bnCN¥2.20bnCN¥1.93bnCN¥1.60bnCN¥1.43bnCN¥1.06bnCN¥848.3mCN¥696.9m
Cash and short-term investments—CN¥1.31bnCN¥1.29bnCN¥1.14bnCN¥1.02bnCN¥890.7mCN¥792.1mCN¥460.0mCN¥185.8mCN¥235.5m
Total liabilitiesCN¥185.7mCN¥250.3mCN¥258.5mCN¥170.8mCN¥135.4mCN¥76.6mCN¥76.3mCN¥62.5mCN¥47.1mCN¥41.3m
Debt—CN¥20.6mCN¥55.6mCN¥16.3mCN¥7.8mCN¥9.8m————
Shareholders' equityCN¥2.62bnCN¥2.35bnCN¥2.19bnCN¥1.98bnCN¥1.74bnCN¥1.46bnCN¥1.27bnCN¥969.5mCN¥801.3mCN¥655.6m
Shares outstanding524m524m524m524m524m523m524m524m524m523m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥423.2mCN¥262.4mCN¥388.3mCN¥360.3mCN¥360.6mCN¥256.2mCN¥232.9mCN¥206.5mCN¥159.1mCN¥122.8m
Capital spending−CN¥119.3m−CN¥118.0m−CN¥209.2m−CN¥188.7m−CN¥122.2m−CN¥70.2m−CN¥99.8m−CN¥57.8m−CN¥34.7m−CN¥35.9m
Free cash flowCN¥303.8mCN¥144.5mCN¥179.2mCN¥171.5mCN¥238.4mCN¥186.1mCN¥133.1mCN¥148.7mCN¥124.4mCN¥86.8m
Dividends paid−CN¥115.3m−CN¥97.4m−CN¥104.7m−CN¥105.2m−CN¥83.8m−CN¥94.2m−CN¥72.7m−CN¥64.6m−CN¥40.4m−CN¥56.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥261.3mCN¥252.8mCN¥209.0mCN¥369.1mCN¥255.8mCN¥228.5mCN¥195.2mCN¥301.0m
Gross profitCN¥249.1mCN¥240.8mCN¥197.9mCN¥353.4mCN¥244.0mCN¥216.5mCN¥185.0mCN¥288.0m
Operating incomeCN¥105.0mCN¥101.4mCN¥34.1mCN¥186.8mCN¥116.6mCN¥84.8mCN¥52.9mCN¥143.7m
Net incomeCN¥94.2mCN¥119.2mCN¥36.1mCN¥167.9mCN¥102.7mCN¥74.3mCN¥45.6mCN¥123.0m
Diluted earnings per share0.180.230.070.320.200.140.090.23
Cash from operations———CN¥88.0mCN¥114.0mCN¥85.0m—CN¥59.0m
Capital spending−CN¥7.0m−CN¥19.0m−CN¥8.0m−CN¥22.0m−CN¥42.0m−CN¥45.0m−CN¥19.0m−CN¥24.0m
Free cash flow———CN¥66.0mCN¥72.0mCN¥40.0m—CN¥35.0m
Total assetsCN¥3.08bnCN¥2.94bnCN¥2.90bnCN¥2.89bnCN¥2.79bnCN¥2.68bnCN¥2.71bnCN¥2.70bn
Cash and short-term investments———CN¥1.34bnCN¥1.36bnCN¥1.29bnCN¥1.31bnCN¥1.25bn
Debt———CN¥9.7mCN¥5.1mCN¥5.1mCN¥12.6mCN¥37.2m
Shareholders' equityCN¥2.75bnCN¥2.74bnCN¥2.62bnCN¥2.64bnCN¥2.47bnCN¥2.43bnCN¥2.35bnCN¥2.36bn

Financial ratios

Data as of 2 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2011FY2010
Gross margin95.2%95.2%95.3%95.3%95.7%95.5%——
Operating margin39.0%39.9%40.7%44.2%48.6%50.5%——
Net margin35.9%34.3%36.6%38.9%41.8%43.8%——
Return on equity14.5%13.5%14.2%17.6%19.5%19.1%——
Return on assets13.1%11.7%12.1%15.9%17.5%17.4%——
Free cash flow yield5.1%3.6%5.6%5.2%4.5%3.1%——
Revenue growth14.8%9.1%-5.3%10.9%27.0%-0.5%——
Earnings growth19.9%2.5%-11.1%3.2%21.4%-6.7%——
Current ratio12.18x9.05x8.87x14.38x12.42x21.13x——
Debt to equity—0.01x0.02x———0.08x0.11x
Equity ratio90.4%86.9%85.3%90.1%89.9%90.7%——
Interest coverage522.68x277.47x233.54x892.39x806.87x3221.66x——
R&D as a share of sales11.0%13.0%13.2%11.8%10.9%10.2%——
Buybacks as a share of market value-0.0%0.0%0.0%-0.0%-0.0%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.8%10.8%14.8%
Operating income1.5%5.2%11.9%
Net income3.0%6.5%12.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin95.2%95.2%95.3%95.5%
Operating margin39.4%40.9%43.3%46.1%
Net margin35.2%36.4%38.1%40.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings38.933.549.082.888.8144.277.546.242.743.8
Price to sales14.011.517.932.237.163.136.221.520.618.1

Dividends and splits

Per share, in the currency the company pays

Paid for 12 years. Last went ex-dividend on 9 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.150.220.2850.200.2010.160.180.139
  • 9-for-5 split · 8 May 2019
  • 9-for-5 split · 19 Apr 2018
  • 8-for-5 split · 23 May 2014

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.